Abstract
Accelerated bone loss is a common clinical feature of advanced breast cancer, and anti-resorptive bisphosphonates are the current standard therapy used to reduce the number and frequency of skeletal-related complications experienced by patients. Bisphosphonates are potent inhibitors of bone resorption, acting by inducing osteoclast apoptosis and thereby preventing the development of cancer-induced bone lesions. In clinical use bisphosphonates are mainly considered to be bone-specific agents, but anti-tumour effects have been reported in a number of in vitro and in vivo studies. By combining bisphosphonates with chemotherapy agents, growth and progression of breast cancer bone metastases can be virtually eliminated in model systems. Recent clinical trials have indicated that there may be additional benefits from bisphosphonate treatment, including positive effects on recurrence and survival when added to standard endocrine therapy. Whereas the ability of bisphosphonates to reduce cancer-induced bone disease is well established, their potential direct anti-tumour effect remain controversial. Ongoing clinical trials will establish whether bisphosphonates can inhibit the development of bone metastases in high-risk breast cancer patients. This review summarizes the main studies that have investigated the effects of bisphosphonates, alone and in combination with other anti-cancer agents, using in vivo model systems of breast cancer bone metastases. We also give an overview of the use of bisphosphonates in the treatment of breast cancer, including examples of key clinical trials. The potential side effects and future clinical applications of bisphosphonates will be outlined.
Keywords: Bone metastases, bisphosphonates, osteoclasts, osteonecrosis, bone resorption
Current Pharmaceutical Design
Title: Bisphosphonates as Treatment of Bone Metastases
Volume: 16 Issue: 11
Author(s): Ingunn Holen and Robert E. Coleman
Affiliation:
Keywords: Bone metastases, bisphosphonates, osteoclasts, osteonecrosis, bone resorption
Abstract: Accelerated bone loss is a common clinical feature of advanced breast cancer, and anti-resorptive bisphosphonates are the current standard therapy used to reduce the number and frequency of skeletal-related complications experienced by patients. Bisphosphonates are potent inhibitors of bone resorption, acting by inducing osteoclast apoptosis and thereby preventing the development of cancer-induced bone lesions. In clinical use bisphosphonates are mainly considered to be bone-specific agents, but anti-tumour effects have been reported in a number of in vitro and in vivo studies. By combining bisphosphonates with chemotherapy agents, growth and progression of breast cancer bone metastases can be virtually eliminated in model systems. Recent clinical trials have indicated that there may be additional benefits from bisphosphonate treatment, including positive effects on recurrence and survival when added to standard endocrine therapy. Whereas the ability of bisphosphonates to reduce cancer-induced bone disease is well established, their potential direct anti-tumour effect remain controversial. Ongoing clinical trials will establish whether bisphosphonates can inhibit the development of bone metastases in high-risk breast cancer patients. This review summarizes the main studies that have investigated the effects of bisphosphonates, alone and in combination with other anti-cancer agents, using in vivo model systems of breast cancer bone metastases. We also give an overview of the use of bisphosphonates in the treatment of breast cancer, including examples of key clinical trials. The potential side effects and future clinical applications of bisphosphonates will be outlined.
Export Options
About this article
Cite this article as:
Holen Ingunn and E. Coleman Robert, Bisphosphonates as Treatment of Bone Metastases, Current Pharmaceutical Design 2010; 16 (11) . https://dx.doi.org/10.2174/138161210791034003
DOI https://dx.doi.org/10.2174/138161210791034003 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Functions of F-box Proteins in Regulating the Epithelial to Mesenchymal Transition
Current Pharmaceutical Design Decoding Novel Mechanisms and Emerging Therapeutic Strategies in Breast Cancer Resistance
Current Drug Metabolism Green Approaches for Cancers Management: An Effective Tool for Health Care
Anti-Cancer Agents in Medicinal Chemistry Cox Inhibitors as Potential Chemotherapic Drugs for Mesothelioma
Current Respiratory Medicine Reviews Methotrexate- and Cyclophosphamide-embedded Pure and Strontiumsubstituted Carbonate Apatite Nanoparticles for Augmentation of Chemotherapeutic Activities in Breast Cancer Cells
Current Drug Delivery Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology ABC Transporters in Extrahepatic Tissues: Pharmacological Regulation in Heart and Intestine
Current Medicinal Chemistry Mechanisms for Radioprotection by Melatonin; Can it be Used as a Radiation Countermeasure?
Current Molecular Pharmacology Synthesis and Biological Activities of Some Novel 2-Amino-(5 or 7-Substituted- 2-Oxoindolin-3-Ylidene) Benzoxazole-5-Carbohydrazide Derivatives
Letters in Drug Design & Discovery Graphical Abstracts:
Current Medical Imaging Biosynthesis of Copper Oxide Nanoparticles Using Lactobacillus casei Subsp. Casei and its Anticancer and Antibacterial Activities
Current Nanoscience Evaluation of Novel Radioiodinated C7-substituted Δ6,7 – estradiol Derivatives for Molecular Recognition of ER-Positive Breast Tumours
Current Radiopharmaceuticals HClO4-SiO2: A Highly Efficient and Recyclable Catalyst for the Selective α-Bromination of Carbonyl Compounds Using N-Bromosuccinimide
Letters in Organic Chemistry Classification Methods in Chemometrics
Current Analytical Chemistry Infection and Anemia
Infectious Disorders - Drug Targets Novel Compounds from Marine Microorganisms that Inhibit Mammalian DNA Polymerase
Current Organic Chemistry Voltage-Dependent Potassium Channels Kv1.3 and Kv1.5 in Human Cancer
Current Cancer Drug Targets Anticancer Properties of Amino Acid and Peptide Derivatives of Mycophenolic Acid
Anti-Cancer Agents in Medicinal Chemistry Recent Progress of Novel Steroid Derivatives and Their Potential Biological Properties
Mini-Reviews in Medicinal Chemistry Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets